{"id":989098,"date":"2026-08-04T07:18:32","date_gmt":"2026-08-04T11:18:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/"},"modified":"2026-08-04T07:18:32","modified_gmt":"2026-08-04T11:18:32","slug":"neuraxis-expands-payer-coverage-with-new-policies","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/","title":{"rendered":"NeurAxis Expands Payer Coverage with New Policies"},"content":{"rendered":"
\n

CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) — NeurAxis, Inc. (\u201cNeurAxis\u201d or the \u201cCompany\u201d) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region.<\/p>\n

\u201cAs we continue to make meaningful progress with the nation’s largest payers, adding coverage from regional health plans like these broadens patient access and strengthens our reimbursement network,\u201d said Brian Carrico, CEO of NeurAxis. \u201cWe continue to build momentum toward comprehensive nationwide written policy coverage for IB-Stim. The implementation of the Category I CPT code, together with the inclusion of our PENFS technology in leading clinical guidelines, is reinforcing IB-Stim’s clinical and economic value among payers. Supported by a strong balance sheet, we are well positioned to expand our commercial organization as reimbursement coverage grows and demand for IB-Stim continues to increase.\u201d<\/p>\n

NeurAxis\u2019 proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia, and FD associated nausea symptoms, in patients 8 years and older. IB-Stim is a non-invasive neuromodulation device that gently stimulates cranial nerve bundles in the ear to help regulate pain signaling between the gut and the brain. Currently, no FDA-approved drug therapies exist for pediatric patients with abdominal pain-related disorders of gut-brain interaction (DGBIs), a significant unmet medical need. In the absence of approved options, off-label prescription drugs are often used, despite limited efficacy data and potential safety concerns\u2014underscoring IB-Stim\u2019s unique position as the only FDA-cleared therapy specifically designed for this large and underserved pain related patient population.<\/p>\n

\n About NeurAxis, Inc.<\/strong>\n <\/p>\n

NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of IB-Stim, its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA-cleared for functional abdominal pain in irritable bowel syndrome (IBS) and functional dyspepsia, including FD-linked nausea symptoms in patients ages 8 and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http:\/\/neuraxis.com<\/a>.<\/p>\n

\n Forward-Looking Statements <\/strong>\n <\/p>\n

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management\u2019s current assumptions and expectations of future events and trends, which affect or may affect the Company\u2019s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company\u2019s stock, public health issues or other events, the Company\u2019s compliance with applicable laws, the results of the Company\u2019s clinical trials and perceptions thereof, the results of submissions to the FDA, and factors described in the Risk Factors section of NeurAxis\u2019s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.<\/p>\n

For contraindications, precautions, warnings, and IFU, please see: https:\/\/ibstim.com\/important-information\/<\/a>.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

\n Company<\/strong>
\n
\n NeurAxis, Inc.<\/strong>
\n
\n info@neuraxis.com<\/a>\u00a0<\/p>\n

\n Investor Relations<\/strong>
\n
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) — NeurAxis, Inc. (\u201cNeurAxis\u201d or the \u201cCompany\u201d) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region. \u201cAs we continue to make meaningful progress with the nation’s largest payers, adding coverage from regional health plans like these broadens patient access and strengthens our reimbursement network,\u201d said Brian Carrico, CEO of NeurAxis. \u201cWe continue to build momentum toward comprehensive nationwide written policy coverage for IB-Stim. The implementation of the Category I CPT … <\/p>\n

Continue reading “NeurAxis Expands Payer Coverage with New Policies”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-989098","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNeurAxis Expands Payer Coverage with New Policies - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeurAxis Expands Payer Coverage with New Policies - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) — NeurAxis, Inc. (\u201cNeurAxis\u201d or the \u201cCompany\u201d) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region. \u201cAs we continue to make meaningful progress with the nation’s largest payers, adding coverage from regional health plans like these broadens patient access and strengthens our reimbursement network,\u201d said Brian Carrico, CEO of NeurAxis. \u201cWe continue to build momentum toward comprehensive nationwide written policy coverage for IB-Stim. The implementation of the Category I CPT … Continue reading "NeurAxis Expands Payer Coverage with New Policies"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-04T11:18:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjcxNSM3NzU2MTY0IzIyNTIyNDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-expands-payer-coverage-with-new-policies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-expands-payer-coverage-with-new-policies\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeurAxis Expands Payer Coverage with New Policies\",\"datePublished\":\"2026-08-04T11:18:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-expands-payer-coverage-with-new-policies\\\/\"},\"wordCount\":723,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-expands-payer-coverage-with-new-policies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMjcxNSM3NzU2MTY0IzIyNTIyNDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-expands-payer-coverage-with-new-policies\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-expands-payer-coverage-with-new-policies\\\/\",\"name\":\"NeurAxis Expands Payer Coverage with New Policies - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-expands-payer-coverage-with-new-policies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-expands-payer-coverage-with-new-policies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMjcxNSM3NzU2MTY0IzIyNTIyNDI=\",\"datePublished\":\"2026-08-04T11:18:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-expands-payer-coverage-with-new-policies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-expands-payer-coverage-with-new-policies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-expands-payer-coverage-with-new-policies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMjcxNSM3NzU2MTY0IzIyNTIyNDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMjcxNSM3NzU2MTY0IzIyNTIyNDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-expands-payer-coverage-with-new-policies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeurAxis Expands Payer Coverage with New Policies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeurAxis Expands Payer Coverage with New Policies - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/","og_locale":"en_US","og_type":"article","og_title":"NeurAxis Expands Payer Coverage with New Policies - Market Newsdesk","og_description":"CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) — NeurAxis, Inc. (\u201cNeurAxis\u201d or the \u201cCompany\u201d) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region. \u201cAs we continue to make meaningful progress with the nation’s largest payers, adding coverage from regional health plans like these broadens patient access and strengthens our reimbursement network,\u201d said Brian Carrico, CEO of NeurAxis. \u201cWe continue to build momentum toward comprehensive nationwide written policy coverage for IB-Stim. The implementation of the Category I CPT … Continue reading \"NeurAxis Expands Payer Coverage with New Policies\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-04T11:18:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjcxNSM3NzU2MTY0IzIyNTIyNDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeurAxis Expands Payer Coverage with New Policies","datePublished":"2026-08-04T11:18:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/"},"wordCount":723,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjcxNSM3NzU2MTY0IzIyNTIyNDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/","name":"NeurAxis Expands Payer Coverage with New Policies - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjcxNSM3NzU2MTY0IzIyNTIyNDI=","datePublished":"2026-08-04T11:18:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjcxNSM3NzU2MTY0IzIyNTIyNDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMjcxNSM3NzU2MTY0IzIyNTIyNDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-expands-payer-coverage-with-new-policies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeurAxis Expands Payer Coverage with New Policies"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/989098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=989098"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/989098\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=989098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=989098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=989098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}